StreetInsider.com News Articles

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Mon, 31 Aug 2026 08:00:00 -0400

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.

H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat
Date: Monday, September 14, 2026
Time: 2:00 PM ET

The live webcast and replay of the presentation will

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Mon, 31 Aug 2026 08:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat
Date: Monday, September 14, 2026
Time: 2:00 PM ET

The live webcast and replay of the presentation will

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Mon, 24 Aug 2026 08:00:00 -0400

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21^st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.

Wells Fargo 21^st Annual Healthcare Conference
Format: One-on-one Meetings
Date: Thursday, September 10, 2026

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq:

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Mon, 24 Aug 2026 08:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference
Format: One-on-one Meetings
Date: Thursday, September 10, 2026

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq:

H.C. Wainwright Reiterates Buy Rating on Elicio Therapeutics (ELTX)

Tue, 18 Aug 2026 06:42:57 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $23.00 price target on Elicio Therapeutics (NASDAQ: ELTX).

The analyst commented: "For 2Q26, Elicio Therapeutics reported a net loss of $0.43 per share—in line with our previously estimated net loss of $0.45 per share. R&D and SG&A expenses were $6.8M and $3.6M, respectively, vs. our estimates of $6.1M and $3.9M. We now project a full-year 2026 net loss of $1.83 per share vs. our prior net loss estimate of $1.82 per share. Elicio ended 2Q26 with pro forma cash, cash equivalents, and marketable securities of ~$37.5M, which includes the recent registered

Form 10-Q Elicio Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921009.html

Form 10-Q Elicio Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921009.html

Form 8-K Elicio Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920941.html

Form 8-K Elicio Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920941.html

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 16:01:00 -0400

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026

While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma (“PDAC”)
Memorial Sloan Kettering Cancer Center-led Phase 1 trial activated evaluating ELI-002 7P plus chemotherapy

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 16:01:00 -0400

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026

While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma (“PDAC”)
Memorial Sloan Kettering Cancer Center-led Phase 1 trial activated evaluating ELI-002 7P plus chemotherapy

Elicio starts Phase 1 pancreatic cancer study of ELI-002 7P

Mon, 10 Aug 2026 08:00:29 -0400

Elicio Therapeutics (NASDAQ: ELTX) has opened a Phase 1 investigator-initiated trial evaluating its cancer immunotherapy ELI-002 7P in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC), according to a company statement.

The multi-center study, identified as NCT07671339, is being conducted by Memorial Sloan Kettering Cancer Center and funded through a partnership between The Lustgarten Foundation and Break Through Cancer. The trial aims to enroll 20 patients with KRAS-mutant PDAC.

Participants will receive ELI-002 7P combined with the standard chemotherapy regimen mFOLFIRINOX, with or without tislelizumab, an anti-PD1 checkpoint inhibitor, beginning before surgery. Researchers plan to collect tumor tissue and blood

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Mon, 10 Aug 2026 08:00:00 -0400

Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation
Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant setting
Expected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (“PDAC”)

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study (NCT07671339)

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Mon, 10 Aug 2026 08:00:00 -0400

Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation
Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant setting
Expected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (“PDAC”)

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study (NCT07671339)

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Mon, 10 Aug 2026 08:00:00 -0400

Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation
Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant setting
Expected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (“PDAC”)

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study (NCT07671339)

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Mon, 10 Aug 2026 08:00:00 -0400

Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation
Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant setting
Expected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (“PDAC”)

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study (NCT07671339)

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Shah Preetam

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784474.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Shah Preetam

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784474.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: DeMuth Peter

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784476.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: DeMuth Peter

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784476.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Haqq Christopher

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784481.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Haqq Christopher

Fri, 17 Jul 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260717/26784481.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Connelly Robert

Fri, 17 Jul 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260717/26784472.html

Form 4 Elicio Therapeutics, For: Jul 16 Filed by: Connelly Robert

Fri, 17 Jul 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260717/26784472.html

Form SCHEDULE 13G Elicio Therapeutics, Filed by: Moti Investments LLC

Thu, 16 Jul 2026 11:42:00 -0400
si-local-file:///var/storage/secattach/20260716/26778368.html